{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T22:22:54Z","timestamp":1781389374181,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00380-025-02571-1","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T11:43:10Z","timestamp":1752234190000},"page":"1101-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors correlated with non-early achievement of target low-density lipoprotein cholesterol level using PCSK9 inhibitors"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-7023","authenticated-orcid":false,"given":"Masami","family":"Nishino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Egami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Ohsuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shodai","family":"Kawanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Matsunaga-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"2571_CR1","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Fugar S, Generoso G, Heard DG, Hiremath S, Ho JE, Kalani R, Kazi DS, Ko D, Levine DA, Liu J, Ma J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge MP, Thacker EL, Virani SS, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Martin SS (2023) Heart disease and stroke statistics-2023 update: a report from the american heart association. Circulation 147:e93\u2013e621","journal-title":"Circulation"},{"key":"2571_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2991\/jegh.k.201217.001","volume":"11","author":"U Ralapanawa","year":"2021","unstructured":"Ralapanawa U, Sivakanesan R (2021) Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health 11:169\u2013177","journal-title":"J Epidemiol Glob Health"},{"key":"2571_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Bor\u00e9n J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokg\u00f6zoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38:2459\u20132472","journal-title":"Eur Heart J"},{"key":"2571_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00380-024-02359-9","volume":"39","author":"H Amano","year":"2024","unstructured":"Amano H, Kojima Y, Hirano S, Oka Y, Aikawa H, Noike R, Yabe T, Okubo R, Ikeda T (2024) The impact of statins treatments for plaque characteristics in stable angina pectoris patients with very low and high low-density lipoprotein cholesterol levels: an intracoronary optical coherence tomography study. Heart Vessels 39:475\u2013485","journal-title":"Heart Vessels"},{"key":"2571_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, R\u00e4ber L, Mach F, Windecker S (2018) Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 39:1172\u20131180","journal-title":"Eur Heart J"},{"key":"2571_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489\u20131499","journal-title":"N Engl J Med"},{"key":"2571_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713\u20131722","journal-title":"N Engl J Med"},{"key":"2571_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce ardiovascular risk. Eur Heart J 41:111\u2013188","journal-title":"Eur Heart J"},{"key":"2571_CR9","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, H\u00e4ner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, R\u00e4ber L, Heg D, Mach F (2019) Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol 74:2452\u20132462","journal-title":"J Am Coll Cardiol"},{"key":"2571_CR10","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstr\u00f8m T, Lang IM, Koskinas KC (2022) Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 327:1771\u20132178","journal-title":"JAMA"},{"key":"2571_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1536\/ihj.22-052","volume":"63","author":"Y Hao","year":"2022","unstructured":"Hao Y, Yang YL, Wang YC, Li J (2022) Effect of the early application of Evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome. Int Heart J 63:669\u2013677","journal-title":"Int Heart J"},{"key":"2571_CR12","first-page":"1408","volume":"44","author":"GG Schwartz","year":"2023","unstructured":"Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, Fazio S, Fras Z, Goodman SG, Harrington RA, Jukema JW, Manvelian G, Pordy R, Ray KK, Scemama M, White HD, Steg PG (2023) Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Eur Heart J 44:1408\u20131417","journal-title":"Eur Heart J"},{"key":"2571_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00380-024-02473-8","volume":"40","author":"T Shimizu","year":"2025","unstructured":"Shimizu T, Morishita T, Uzui H, Sato Y, Kataoka T, Miyoshi M, Yamaguchi J, Shiomi Y, Ikeda H, Tama N, Hasegawa K, Ishida K, Tada H (2025) Anti-inflammatory effects of proprotein convertase subtilisin\/kexin 9 inhibitor therapy in the early phase of acute myocardial infarction. Heart Vessels 40:312\u2013319","journal-title":"Heart Vessels"},{"key":"2571_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106439","volume":"184","author":"N Ferri","year":"2022","unstructured":"Ferri N, Ruscica M, Lupo MG, Vicenzi M, Sirtori CR, Corsini A (2022) Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. Pharmacol Res 184:106439","journal-title":"Pharmacol Res"},{"key":"2571_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1253\/circj.CJ-23-0285","volume":"88","author":"A Fujiyoshi","year":"2024","unstructured":"Fujiyoshi A, Kohsaka S, Hata J, Hara M, Kai H, Masuda D, Miyamatsu N, Nishio Y, Ogura M, Sata M, Sekiguchi K, Takeya Y, Tamura K, Wakatsuki A, Yoshida H, Fujioka Y, Fukazawa R, Hamada O, Higashiyama A, Kabayama M, Kanaoka K, Kawaguchi K, Kosaka S, Kunimura A, Miyazaki A, Nii M, Sawano M, Terauchi M, Yagi S, Akasaka T, Minamino T, Miura K, Node K (2024) JCS 2023 guideline on the primary prevention of coronary artery disease. Circ J 88:763\u2013842","journal-title":"Circ J"},{"key":"2571_CR16","doi-asserted-by":"crossref","unstructured":"Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26 Suppl 1: S5\u201320.","DOI":"10.2337\/diacare.26.2007.S5"},{"key":"2571_CR17","doi-asserted-by":"publisher","first-page":"1138787","DOI":"10.3389\/fcvm.2023.1138787","volume":"10","author":"H Chen","year":"2023","unstructured":"Chen H, Chen X (2023) PCSK9 inhibitors for acute coronary syndrome: the era of early implementation. Front Cardiovasc Med 10:1138787","journal-title":"Front Cardiovasc Med"},{"key":"2571_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.amjcard.2023.10.043","volume":"213","author":"GB Justino","year":"2024","unstructured":"Justino GB, Justino LB, M\u00fcller ME, Rocha AV, Mazetto A, Cardoso R, Leucker TM (2024) Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis. Am J Cardiol 213:110\u2013118","journal-title":"Am J Cardiol"},{"key":"2571_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.101043","volume":"47","author":"C Krittanawong","year":"2022","unstructured":"Krittanawong C, Khawaja M, Rosenson RS, Amos CI, Nambi V, Lavie CJ, Virani SS (2022) Association of PCSK9 variants with the risk of atherosclerotic cardiovascular disease and variable responses to PCSK9 inhibitor therapy. Curr Probl Cardiol 47:101043","journal-title":"Curr Probl Cardiol"},{"key":"2571_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.03.013","volume":"384","author":"AMH Galema-Boers","year":"2023","unstructured":"Galema-Boers AMH, Mulder J, Steward K, Roeters van Lennep JE (2023) Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: a real-world registry. Atherosclerosis 384:117108","journal-title":"Atherosclerosis"},{"key":"2571_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","volume":"22","author":"RS Rosenson","year":"1993","unstructured":"Rosenson RS (1993) Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22:933\u2013940","journal-title":"J Am Coll Cardiol"},{"key":"2571_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jacc.2007.11.075","volume":"51","author":"B Pitt","year":"2008","unstructured":"Pitt B, Loscalzo J, Ycas J, Raichlen JS (2008) Lipid levels after acute coronary syndromes. J Am Coll Cardiol 51:1440\u20131445","journal-title":"J Am Coll Cardiol"},{"key":"2571_CR23","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","volume":"18","author":"SR Mehta","year":"2022","unstructured":"Mehta SR, Pare G, Lonn EM, Jolly SS, Natarajan MK, Pinilla-Echeverri N, Schwalm JD, Sheth TN, Sibbald M, Tsang M, Valettas N, Velianou JL, Lee SF, Ferdous T, Nauman S, Nguyen H, McCready T, McQueen MJ (2022) Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention 18:e888\u2013e896","journal-title":"EuroIntervention"},{"key":"2571_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069116","volume":"377","author":"SU Khan","year":"2022","unstructured":"Khan SU, Yedlapati SH, Lone AN, Hao Q, Guyatt G, Delvaux N, Bekkering GET, Vandvik PO, Riaz IB, Li S, Aertgeerts B, Rodondi N (2022) PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ 377:e069116","journal-title":"BMJ"},{"key":"2571_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.diabet.2019.101120","volume":"46","author":"FJ Tinahones","year":"2020","unstructured":"Tinahones FJ, Laufs U, Cariou B, Louie MJ, Yang J, Thompson D, Leiter LA (2020) Alirocumab efficacy and safety by body mass index: a pooled analysis from 10 phase 3 ODYSSEY trials. Diabetes Metab 46:280\u2013287","journal-title":"Diabetes Metab"},{"key":"2571_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MCA.0000000000000438","volume":"28","author":"JJ Kastelein","year":"2017","unstructured":"Kastelein JJ, Kereiakes DJ, Cannon CP, Bays HE, Minini P, Lee LV, Maroni J, Farnier M (2017) Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coron Artery Dis 28:190\u2013197","journal-title":"Coron Artery Dis"},{"key":"2571_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173114","volume":"878","author":"E Gallego-Colon","year":"2020","unstructured":"Gallego-Colon E, Daum A, Yosefy C (2020) Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol 878:173114","journal-title":"Eur J Pharmacol"},{"key":"2571_CR28","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","volume":"137","author":"I Taguchi","year":"2018","unstructured":"Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R (2018) High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation 137:1997\u20132009","journal-title":"Circulation"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-025-02571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-025-02571-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-025-02571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:18:30Z","timestamp":1764062310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-025-02571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1007\/s00380-025-02571-1","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}